CD44 inactivation reprograms pancreatic cancer fibroblasts and shrinks tumors
Start here
Researchers at the Karlsruhe Institute of Technology have shown that inactivating CD44 in mouse models and human cells reprograms pancreatic cancer-associated fibroblasts, removing their immunosuppressive function and significantly shrinking tumors. Published in Cell Death & Disease, the mechanistic study points to CD44 in stromal cells as a potential target for pancreatic cancer therapy. Pancreatic tumors typically rely on a dense, immunosuppressive microenvironment, so a strategy that disarms cancer-associated fibroblasts rather than simply killing them could complement existing treatments. The findings are preclinical, based on mouse models and human cell experiments; translation into a clinical therapy has not yet been demonstrated.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- medicalxpress.comReprogramming tumor microenvironment could improve prospects for treatment of pancreatic cancer
Researchers at the Karlsruhe Institute of Technology (KIT) have shown that inactivating CD44 in mouse models and human cells reprograms pancreatic cancer-associated fibroblasts, abolishing their immunosuppressive function and significantly shrinking tumors. The mechanistic study, published in Cell Death & Disease, suggests that targeting CD44 in stromal cells offers a new angle for pancreatic cancer therapy.
Heat trend for this story
Heat now 7·Peak in the comparable set 10 (Oct 24 04:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.